PCHはPVODよりもさらに少なく，まとまった報告は少ない[3]。当院でのPVOD/PCH例は男性が約8割を占め，平均年齢47歳である。

PVODとPCHの発症の原因は完全には解明されていない。PVODでは，喫煙，ウイルス感染や毒物，抗癌薬や骨髄移植との関連が指摘されている[2]。PCHの肺組織では，特発性PAHにおいて重要な役割を果たすplatelet-derived growth factorとその受容体の発現が亢進しており，PAHと同様の機序で病態が進行する可能性がある[3]。また，特発性PAHと関連するbone morphogenetic protein receptor 2の遺伝子異常の報告もある[4]。最近，異なる2つのグループの研究から，PVODとPCHの家族内発症例で同一の遺伝子異常が同定され[5][6]，両疾患の病因・病態解明のさらなる進展が期待される。

予後は極めて不良で，PVODは症状発現から2年以内にほぼ全例死亡する[8][9]。PCHも2〜3年で右心不全や呼吸不全により死亡する[3]。急速に悪化し数カ月で死の転帰をとることもある。さまざまな治療薬の登場によりPAHの予後は改善してきているのに対して，PVOD/PCHは診断が困難であるうえに肺高血圧症治療薬の有効性が低く，格差が顕著となっている。

PVOD/PCHは，非常にまれな疾患であるという印象があるが，特発性PAHと臨床的に診断された症例のうち約10%が剖検でPVODと診断されたとする報告もある[10]。実際，当院でもPVOD/PCH症例はPAH症例数の約1割にあたる。また，膠原病関連PAHの中でPAH治療薬への反応不良例に肺静脈病変があるという報告もあり[11]，近年，PVODとの関連が注目されている。

PVODの診断

心臓カテーテル検査で肺高血圧の存在が証明されている症例で，病理組織でPVOD/PCHと診断されれば確定診断となる。肺生検は危険性が高いため生前に確定診断がつくことは通常ないが，PVOD/PCHは，肺高血圧症治療薬に対する反応性や予後が異なるため，PAHとの鑑別が重要である。以下に述べるような特徴的な臨床症状や検査・画像所見などに基づいて，PVOD/PCH疑い症例の臨床診断を早期につけ，治療方針を選択する必要がある。

1 病理組織所見の特徴

PVOD/PCHの確定診断の根拠となるのは病理組織所見である。詳細は「PVODの病理」の項に譲るが，PAHでは肺動脈の内膜・中膜の肥厚を主な特徴とするのに対して，PVODは線維性組織による肺静脈の狭窄/閉塞を特徴とする（**図1a**）[12]。PVOD/PCHともに多層性に増殖した毛細血管が認められ，弱拡大で観察すると，比較的正常な部分の中に病変部分が斑状に散在する像が確認できる（**図1b**）。PCHの特徴は，この多層性の毛細血管が正常構造を破壊しながら浸潤することである[13]。両疾患とも，繰り返す肺胞出血によるヘモジデリンの沈着を認める。

2 臨床所見

A 臨床症状

初発症状は労作時息切れ，呼吸困難が多い。胸部不快感，胸痛，失神なども認められる。PAHでは，膠原病で肺病変を伴う場合を



図 1　PVOD の病理組織像（自験例）

小葉内静脈の著明な狭窄と，その周囲に毛細血管の多層性増殖を認める（弾性線維染色）。
a．肺静脈内に線維成分による高度狭窄を認める（エラスティカマッソン染色）。
b．多層性に増殖した毛細血管腫様病変が斑状に散在する（HE 染色）。



図 2　6 分間歩行試験における酸素飽和度の変化

PVOD/PCH 10 例（a）と特発性 PAH 44 症例（b）の 6 分間歩行試験における酸素飽和度の変化を示す。安静時酸素飽和度も PVOD/PCH では PAH に比較すると有意に低値であり，運動により酸素飽和度がさらに有意に低下している。

除いて，右心不全が進行しない限り著明な低酸素血症を示さないが，PVOD/PCH では，安静時低酸素血症のない例でも，日常生活上の軽労作で酸素飽和度の著明な低下を認める点が特徴的である。安静時から低酸素血症を呈し，ばち指の認められる症例もある。

B 6 分間歩行試験

6 分間歩行試験施行時に著明な酸素飽和度の低下を認める。6 分間継続して歩行すること自体が困難であったり，失神に至ったりする症例もあるので，施行に際しては十分な注意を払う必要がある。当院の PVOD/PCH 例では，6 分間歩行開始前と比較して平均約 10％の酸素飽和度低下を認めた（図 2）。



図 3　PCH 症例の初診時胸部 X 線写真
肺動脈径の拡大を認め，拡大像で Kerley B line を認める（矢印）。

C 呼吸機能検査

呼吸機能検査では軽度の拘束性障害を示す症例が多い。時に閉塞性障害を呈することもある。拡散能（DL_{CO}）の著しい低下が，本疾患に特徴的である。

D 画像所見

詳細は「PVOD における画像所見の特徴」の項に譲るが，胸部 X 線・CT などの画像では，PAH とは異なり，PVOD/PCH に共通した特徴的な所見が認められる。

● 胸部 X 線・CT

胸部 X 線で粒状影の目立つ症例もあるが，病初期には明瞭でない場合もある。下肺野を拡大して注意深く観察すると，Kerley B line を認めることがある（図 3）。胸部単純 CT，特に high-resolution CT（HRCT）では，粒状影や小葉中心性の ground glass opacity（GGO）が認められる[14)15)]。反応性の縦隔リンパ節腫大と胸膜直下の隔壁肥厚，小葉中心性の GGO の 3 徴候が PVOD の診断に有用であるとの報告がある[15)]。ただし，特に病初期においてはこれらの特徴的な所見が当てはまらない症例もあるため注意が必要である。

● 肺換気血流シンチグラフィ

換気シンチグラフィでは欠損像がなく，肺血流シンチグラフィでは，主に上葉を中心とした亜区域性の血流欠損を認め，血流ミスマッチを呈する[16)]。しかしながら，PAH のシンチグラフィと比較して有意差がなかったとする報告もあり[17)]，さらなる検討を要する。時に，慢性血栓塞栓性肺高血圧症で認められるような区域性の大きな血流欠損を呈する症例がある。この場合には，欠損部分に対して選択的肺動脈造影を行い，慢性血栓塞栓性肺高血圧症に特徴的な web や band といった所見がないことを確認する。

E PVOD/PCH 臨床診断スコア

PVOD/PCH の臨床的な特徴に関する報告

はすでに複数あるが，残念ながら見過ごされているケースも多い。早期に臨床診断を行う方法を確立するため，当院で治療を行った肺高血圧症例のうち，PVOD/PCH（臨床診断例を含む）とPAHのさまざまな臨床指標を比較検討し，PVOD/PCHとPAHの鑑別に有用な臨床指標を抽出し，PVOD/PCH臨床診断スコアを作成した[18]。男性，喫煙歴あり，6分間歩行試験中の9%以上の酸素飽和度低下，DL_{CO} 34%未満，胸部HRCTでの小葉中心性GGO，小葉間隔壁肥厚，粒状影，肺血流シンチグラフィでの上葉欠損，の各項目をそれぞれ1点とし，特に疾患特異性の高かった血管拡張薬による肺水腫の既往は2点とした。合計10点のうち4点以上であれば感度94%，特異度91%でPVOD/PCH疑い例を診断することができた。

PVODの治療

PVOD/PCHは診断される症例数が少なく，予後不良であるため，有効な内科的治療法が確立されていない。根本的な治療法は肺移植のみであるが，日本における肺移植の待機期間は約2年であることと，進行の速い症例があることを考慮して，移植希望のある症例では早期に肺移植登録を行う必要がある。

A 支持治療

PAHにおいても支持療法に関するデータやエビデンスは少ないが，PVOD/PCHについてはさらに少ないため，一般的な治療法の考え方を述べる。

上述のようにPVOD/PCHでは低酸素血症を呈するため，酸素投与が必要である。状態の悪化に伴って安静時の低酸素血症も悪化するため，高流量が必要になっていく。抗凝固療法については，PVOD/PCHの病理組織所見で肺胞出血が多く認められることを考慮し，PT-INRを低めにコントロールする。肺胞出血が疑われる場合には即時に中止し，改善した時点で再開する。また，PVOD/PCHでは血流の閉塞機転が肺静脈側にあるため，PAHに比較して肺水腫や胸水貯留が出現しやすい。水分貯留に伴って酸素化が悪化するので，利尿薬を適宜使用する。

B PAH治療薬

PVOD/PCHでは，肺動脈より下流の肺静脈/毛細血管に狭窄・閉塞が存在する。肺動脈を拡張させるPAH治療薬を使用すると，肺細静脈の血管抵抗が下がらないうちに肺小細動脈が拡張し，毛細血管の静水圧が上昇する。これにより肺水腫が惹起される危険性があるため，本疾患に対するPAH治療薬の使用は禁忌と考えられてきた。一方で，近年，PVOD例でPAH治療薬が有効であったという症例報告もあり，PVOD/PCHに対する有効性は確立していない。

エポプロステノールについては，低用量投与では小細動脈圧は上昇するが，6 ng/kg/min以上の投与では肺血管抵抗が低下するとされ[19]，その慎重投与が移植へのブリッジ治療として有効であったという症例報告もある[20]。急激な増量を避け，肺水腫の悪化が認められた場合は，静脈側も拡張し静水圧が低下するまでエポプロステノール増量を中止し利尿薬を併用することで，長期的に緩徐な増量による治療が可能となる。われわれの施設では，PVOD/PCH 8例（全例が後に病理組織



図 4　PVOD 症例の HRCT 画像

40 歳代，男性。当院初診時，労作時の著明な酸素飽和度の低下と肺拡散能低下に加え，HRCT で小粒状影，小葉間隔壁の肥厚，ground glass opacity を認めた (a)。PVOD/PCH の可能性が高いと考えエポプロステノールの導入は見合わせ，イマチニブを開始し移植登録を行った。イマチニブ治療開始 2 年半後には心係数は変化なく，平均肺動脈圧が低下していた。HRCT の所見は改善していた (b)。のちに脳死肺移植を受け，PVOD と確定診断された。

で確定診断された）に対して，エポプロステノールによる治療を行った[21]。平均最大投与量 55.3±10.7 ng/kg/min を，平均投与期間 387.3±116.3 日にわたって投与した結果，全例で一時的に心拍出量が改善し，WHO 機能分類，6 分間歩行距離，BNP 値も改善した。しかしながら，肺動脈圧は低下せず，さらに，エポプロステノールの増量に伴って間質影と酸素化が悪化し，次第に高流量の酸素投与が必要となった。したがって，エポプロステノールは，慎重に低用量で使用するならば移植までのブリッジ治療としては有用であるが，根本的な治療ではない。治療開始後に急激に悪化する危険性もあることから，使用経験の豊富な施設での施行が望ましい。

C 新たな治療薬の可能性

肺高血圧症の病態は，肺血管の収縮と過剰な細胞増殖による血管内腔の狭窄・閉塞による。そのため，血管増殖抑制を目的とした分子標的治療薬の有効性が期待できる。中でも，イマチニブは platelet-derived growth factor 受容体のリン酸化を阻害する薬剤であり，PVOD で有効であったとする症例報告もある[22]。イマチニブは本疾患には保険適用外であるが，当院では自主臨床治験として合計 7

例のPVOD/PCH症例に対して，イマチニブの長期投与を行った。エポプロステノールは投与に伴って間質影の増強が目立ったのに対して，イマチニブでは間質影の増強は認められなかった（図4）。血行動態についても，心係数が低下することなく，平均肺動脈圧は全例で低下した〔56.3±8.9 vs. 39.9±10.8 mmHg（$p<0.05$）〕。治療開始後生存期間は平均4.1±0.7年と改善し，2例では，脳死肺移植へのブリッジ治療となった。強い水分貯留傾向，腎機能障害などの副作用や，適切な症例選択や至適投与量の設定など，今後解決すべき課題も多いが，PVOD/PCHの治療薬として期待できる。また，マルチキナーゼ阻害薬であるソラフェニブは，イマチニブより多くのシグナル伝達経路を阻害するため，イマチニブの反応不良例や二次無効例にも効果的である可能性がある。肺高血圧症の動物モデルやPVOD症例において有効性が報告されている[7][8]。最近報告された遺伝子異常[5][6]に関連して，新たな治療薬の開発が期待される。

まとめ

近年，肺高血圧症治療の進歩が注目を集め，結果として肺高血圧症と診断される症例が増加している。また，経口治療薬の登場により，肺高血圧症治療を多くの施設で受けられるようになってきている。しかしながら，症例数はPAHほど多くないが，通常のPAH治療では改善せず，むしろ悪化する危険性があるPVOD/PCH症例が存在することに留意する。肺高血圧症治療を行う前に，必ずPVOD/PCHの可能性を検討する必要がある。可能性が否定できない場合には，治療経験の豊富な施設と連携しながら治療にあたる。上述したように，現在のところPVOD/PCHに対して長期的に有効性の確立した治療法は存在しないため，本疾患に特異的に有効な治療法の確立が望まれる。

文献

1) Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013 ; 62 : D34-41.
2) Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000 ; 162 : 1964-73.
3) Almagro P, Julia J, Sanjaume M, et al. Pulmonary capillary hemangiomatosis associated with primary pulmonary hypertension : Report of 2 new cases and review of 35 cases from the literature. Medicine (Baltimore) 2002 ; 81 : 417-24.
4) Runo JR, Vnencak-Jones CL, Prince M, et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor ii. Am J Respir Crit Care Med 2003 ; 167 : 889-94.
5) Assaad AM, Kawut SM, Arcasoy SM, et al. Platelet-derived growth factor is increased in pulmonary capillary hemangiomatosis. Chest 2007 ; 131 : 850-5.
6) Eyries M, Montani D, Girerd B, et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014 ; 46 : 65-9.
7) Best DH, Sumner KL, Austin ED, et al. EIF2AK4 mutations in pulmonary capillary hemangiomatosis. Chest (in press).
8) Shackelford GD, Sacks EJ, Mullins JD, et al. Pulmonary venoocclusive disease : case report and review of the literature. AJR Am J Roentgenol 1977 ; 128 : 643-8.
9) Montani D, O'Callaghan DS, Savale L, et al. Pulmonary veno-occlusive disease : recent progress and current challenges. Respir Med 2010 ; 104 : S23-32.
10) Pietra GG, Edwards WD, Kay JM, et al. Histopa-

thology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the national heart, lung, and blood institute, primary pulmonary hypertension registry. Circulation 1989 ; 80 : 1198-206.
11) Dorfmuller P, Humbert M, Perros F, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007 ; 38 : 893-902.
12) Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004 ; 43 : 25S-32S.
13) Lantuejoul S, Sheppard MN, Corrin B, et al. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis : a clinicopathologic study of 35 cases. Am J Surg Pathol 2006 ; 30 : 850-7.
14) Frazier AA, Franks TJ, Mohammed TL, et al. From the archives of the afip : pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Radiographics 2007 ; 27 : 867-82.
15) Resten A, Maitre S, Humbert M, et al. Pulmonary hypertension : CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 2004 ; 183 : 65-70.
16) Bailey CL, Channick RN, Auger WR, et al. "High probability" perfusion lung scans in pulmonary venoocclusive disease. Am J Respir Crit Care Med 2000 ; 162 : 1974-8.
17) Seferian A, Helal B, Jais X, et al. Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. Eur Respir J 2012 ; 40 : 75-83.
18) 小川愛子, 松原広己. Pulmonary veno-occlusive disease と pulmonary capillary hemangiomatosis の診断のポイント. Ther Res 2013 ; 33 : 1532-4.
19) Davis LL, deBoisblanc BP, Glynn CE, et al. Effect of prostacyclin on microvascular pressures in a patient with pulmonary veno-occlusive disease. Chest 1995 ; 108 : 1754-6.
20) Montani D, Jais X, Price LC, et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J 2009 ; 34 : 1348-56.
21) Ogawa A, Miyaji K, Yamadori I, et al. Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Circ J 2012 ; 76 : 1729-36.
22) Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, et al. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J 2008 ; 32 : 232-5.
23) Klein M, Schermuly RT, Ellinghaus P, et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 2008 ; 118 : 2081-90.
24) Kataoka M, Yanagisawa R, Fukuda K, et al. Sorafenib is effective in the treatment of pulmonary veno-occlusive disease. Cardiology 2012 ; 123 : 172-4.

ABSTRACT

Pulmonary Veno-Occlusive Disease : Diagnosis and Treatment

Aiko OGAWA*, Hiromi MATSUBARA*

Pulmonary veno-occlusive disease, together with pulmonary capillary hemangiomatosis, is classified as Group 1' in the clinical classification of pulmonary hypertension. Desaturation upon exertion and characteristic radiographic findings lead to the diagnosis of this disease. There is no proven treatment except lung transplantation. Vasodilators can cause pulmonary edema and should be initiated cautiously in patients with this disease. Here, we review pulmonary veno-occlusive disease, focusing on clinical diagnosis and currently available treatments.

(Authors')

Department of Clinical Science, National Hospital Organization Okayama Medical Center, Okayama

Cardiovascular Pathology 22 (2013) 287–293

Contents lists available at SciVerse ScienceDirect

Cardiovascular Pathology

Original Article

Different sizes of centrilobular ground-glass opacities in chest high-resolution computed tomography of patients with pulmonary veno-occlusive disease and patients with pulmonary capillary hemangiomatosis

Aya Miura [a], Satoshi Akagi [a], Kazufumi Nakamura [a,*], Keiko Ohta-Ogo [b], Katsushi Hashimoto [a], Satoshi Nagase [a], Kunihisa Kohno [a], Kengo Kusano [a], Aiko Ogawa [c], Hiromi Matsubara [c], Shinichi Toyooka [d], Takahiro Oto [d], Aiji Ohtsuka [e], Tohru Ohe [a], Hiroshi Ito [a]

[a] Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
[b] Department of Pathology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
[c] Division of Cardiology, National Hospital Organization Okayama Medical Center, Okayama, Japan
[d] Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
[e] Department of Human Morphology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

ARTICLE INFO

Article history:
Received 10 September 2012
Received in revised form 7 November 2012
Accepted 5 December 2012

Keywords:
Computed tomography
Centrilobular ground-glass opacity
Pulmonary hypertension
Pulmonary veno-occlusive disease
Pulmonary capillary hemangiomatosis

ABSTRACT

Background: Centrilobular ground-glass opacity (GGO) is one of the characteristic findings in chest high-resolution computed tomography (HRCT) of patients with pulmonary veno-occlusive disease (PVOD) and patients with pulmonary capillary hemangiomatosis (PCH). However, clinical differential diagnosis of these two diseases is difficult and has not been established. In order to clarify their differences, we compared the sizes of GGOs in chest HRCT and the sizes of capillary assemblies in pulmonary vascular casts between patients diagnosed pathologically with PVOD and PCH.
Methods: We evaluated chest HRCT images for four patients with idiopathic pulmonary arterial hypertension (IPAH), three patients with PVOD and three patients with PCH, and we evaluated pulmonary vascular casts of lung tissues obtained from those patients at lung transplantation or autopsy.
Results: Centrilobular GGOs in chest HRCT were observed in patients with PVOD and patients with PCH but not in patients with IPAH. We measured the longest diameter of the GGOs. The size of centrilobular GGOs was significantly larger in patients with PCH than in patients with PVOD (5.60±1.43 mm versus 2.51±0.79 mm, $P<.01$). We succeeded in visualization of the 3-dimensional structures of pulmonary capillary vessels obtained from the same patients with PVOD and PCH undergoing lung transplantation or autopsy and measured the diameters of capillary assemblies. The longest diameter of capillary assemblies was also significantly larger in patients with PCH than in patients with PVOD (5.44±1.71 mm versus 3.07±1.07 mm, $P<.01$).
Conclusion: Measurement of the sizes of centrilobular GGOs in HRCT is a simple and useful method for clinical differential diagnosis of PVOD and PCH.

1. Introduction

Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH) are rare diseases that are classified as a subgroup of pulmonary arterial hypertension (PAH) [1–3]. PVOD is histologically characterized by intimal fibrosis that narrows and occludes pulmonary veins and it accounts for 5–10% of cases initially thought to be idiopathic PAH (IPAH) [4]. PVOD occurs in a wide range of ages. Among adult patients, the incidence in men is about twice that in women. PCH is histologically characterized by localized capillary proliferation within the lung in which capillaries invade the pulmonary interstitium, vessels and, less commonly, airways [5]. PCH has been reported to be much less frequent than PVOD [6]. PCH and PVOD have similar clinical presentations with poor prognosis.

In recent years, PAH-targeted drugs including epoprostenol have improved the survival of patients with IPAH [3,7,8], but no medical treatment to improve the survival of patients with PVOD or PCH has been established. Several investigators have reported the possible efficacy of cautious application of epoprostenol [9,10], but incautious administration of vasodilators including epoprostenol sometimes causes massive pulmonary edema and can be fatal in these patients.

This study was supported by the Research Grant for Cardiovascular Diseases (H19-9) from the Ministry of Health, Labour and Welfare, Japan, and in part by a grant to the Respiratory Failure Research Group (H23-24) from the Ministry of Health, Labour and Welfare, Japan.

* Corresponding author. Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kitaku, Okayama 700-8558, Japan. Tel.: +81 86 235 7351; fax: +81 86 235 7353.
E-mail address: chibun@cc.okayama-u.ac.jp (K. Nakamura).

1054-8807/$ – see front matter © 2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.carpath.2012.12.002

Therefore, the establishment of methods for medical treatment in these patients is required. To that end, accurate diagnosis of PVOD and PCH is also needed.

Histological proof is required for a definitive diagnosis of PVOD and PCH. Since surgical lung biopsy is too invasive and is a high risk for patients with PVOD or PCH, a noninvasive approach is preferable. High-resolution computed tomography (HRCT) of the chest is one of the diagnostic tools for PVOD and PCH. Centrilobular ground-glass opacities (GGOs), septal lines and mediastinal lymph node enlargement are characteristic findings in chest HRCT of patients with PVOD or PCH [6,11,12]. However, clinical differential diagnosis of these diseases has not been established.

We previously reported success in visualization of the 3-dimensional structures of pulmonary capillary vessels in patients with PAH, PVOD and PCH using scanning electron microscopy of blood vascular casts [13]. Study of blood vascular casts revealed differences in the three diseases. PAH was characterized by a deficient capillary network, PVOD was characterized by swollen capillary vessels and PCH was characterized by tumor-like outgrowth of capillaries. These differences in capillaries might reflect differences in the sizes of GGOs in chest HRCT since centrilobular GGOs reflect thickening of interstitial tissues, local fluid accumulation in airspaces, local alveoli collapse and increased capillary blood volume [14,15]. Thus, we compared the sizes of centrilobular GGO in chest HRCT and the sizes of capillary assemblies in pulmonary vascular casts in patients diagnosed pathologically with PVOD and patients diagnosed pathologically with PCH in order to clarify their differences.

2. Methods

2.1. Subjects

We obtained lung tissues from 27 patients clinically diagnosed with PAH by living-donor lobar lung transplantation (LDLLT), cadaveric lung transplantation (CLT) or autopsy between 1999 and 2011 in our institution. Twenty patients were diagnosed with pulmonary arteriopathy, four patients were diagnosed with PVOD and three patients were diagnosed with PCH by pathological examination. We could obtain findings of chest HRCT from four patients with idiopathic PAH (IPAH), three patients with PVOD and three patients with PCH before or just after the start of specific treatment for pulmonary hypertension. For non-pulmonary hypertension control experiments, samples of pulmonary arteries were also obtained at autopsy from a patient with cerebral infarction (male, 43 years old) who showed no evidence of PAH.

All human subject protocols were approved by the Human Ethics Committee of Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, and written informed consent was obtained from all patients before the procedure. The investigation also conforms to the principles outlined in the Declaration of Helsinki.

2.2. Histological analysis

Lung tissue was fixed in 10% formalin. Hematoxylin and eosin stain and elastica-van Gieson stain were used for all histological specimens to characterize pulmonary abnormalities. The pathologic hallmark of pulmonary arteriopathy was defined as medial hypertrophy, intimal thickening and plexiform lesions. The pathologic hallmark of PVOD was defined as an extensive and diffuse obstruction of pulmonary venules and veins of various sizes. The pathologic hallmark of PCH was defined as localized capillary proliferation within the lung in which capillaries have invaded the pulmonary interstitium, vessels and, less commonly, airways as previously described [5,16].

2.3. Pulmonary vascular casts

To visualize the 3-dimensional structures of pulmonary vessels, we made vascular casts as previously described [13,17]. In brief, lungs were isolated from patients undergoing lung transplantation or at autopsy, and their pulmonary arteries were cannulated. The pulmonary arteries were then perfused with saline and methacrylate resin (Mercox CL; Oken Shoji, Tokyo, Japan). These resin-injected lungs were placed in a hot water bath to completely polymerize the resin. The lungs with polymerized resin were immersed in a hot 10% NaOH solution and washed in water. This series of maceration and washing was repeated several times until tissue elements had been completely removed. The blood vascular casts of lungs were air-dried, coated with gold, and observed with a scanning electron microscope (S-2300, Hitachi) using an acceleration voltage of 5 kV. Digital images were also obtained with a digital camera (Canon IXY Digital 800IS), and the longest diameter of 14–16 capillary assemblies in the pulmonary vascular casts in each patient were measured.

2.4. Clinical and functional assessment

We obtained clinical data at HRCT of the chest including clinical diagnosis, World Health Organization functional class, pulmonary function test results and PAH-specific treatment from medical records as previously described [13,18–21]. Diffusion capacity of the lung for carbon monoxide (DLco) was measured by the single-breath method and expressed as %DLco (% predicted). We collected hemodynamic data from right heart catheterization performed within one month of HRCT of the chest examination. Event-free survival period was from

Table 1
Patients` characteristics

No.	Age (years old)	Sex	Histological diagnosis	WHO FC	mean PAP (mmHg)	%DLco (%)	Survival (years)	Outcome
1	10	F	IPAH	IV	84	59	0.8	LDLLT
2	27	M	IPAH	IV	50	58	4.0	Autopsy
3	16	M	IPAH	IV	106	79	11.7	CLT
4	20	F	IPAH	IV	58	81	3.7	LDLLT
5	41	M	PVOD	IV	39	24	2.0	Autopsy
6	32	F	PVOD	IV	57	23	1.2	LDLLT
7	26	M	PVOD	IV	57	31	0.4	Autopsy
8	11	M	PCH	IV	52	64	3.1	Autopsy
9	17	F	PCH	IV	NA	NA	0.1	Autopsy
10	25	F	PCH	IV	55	36	0.4	LDLLT

Age, age at chest CT examination; WHO FC, World Health Organization classification of functional status of patients with pulmonary hypertension; PAP, pulmonary artery pressure; %DLCO, diffusion capacity of the lung for carbon monoxide expressed as % predicted; survival, period between diagnosis and outcome; CLT, cadaveric lung transplantation; LDLLT, living-donor lobar lung transplantation; F, female; M, male; PAH, pulmonary arterial hypertension; PVOD, pulmonary veno-occlusive disease; PCH, pulmonary capillary hemangiomatosis; NA, not available.

diagnosis to an event (LDLLT, CLT or death). Chest radiography was performed at the same time as HRCT of the chest.

2.5. HRCT of the chest

HRCT of the chest was performed before or just after the start of PAH-specific treatment in all patients and at the time of the most recent follow-up from lung transplantation or death in three patients with IPAH (patient No. 1, 3 and 4), two patients with PVOD (patient No. 5 and 7) and patients with PCH. Follow-up HRCT of the chest was not performed in patient No. 2 and 6. CT scans were performed with a SOMATOM HiQ scanner (Siemens Healthcare, Germany), HiSpeed Advantage scanner (GE Medical Systems, Milwaukee, WI, USA) and Aquilion 16 scanner (Toshiba Medical Systems Corporation, Tokyo, Japan) from 1999 to 2009 and with an Aquilion 64 scanner (Toshiba Medical Systems Corporation, Tokyo, Japan) and SOMATOM Definition Flash scanner (Siemens Healthcare, Germany) from 2010 to 2012 at end inspiration with patients in the supine position. Thin-section CT was performed with 1-mm section thickness at 10-mm intervals. Scans were photographed with both soft-tissue (level, 30 H; width, 350 H) and lung (level, −600 H; width, 1600 H) window settings. Two radiologists reviewed the thin-section CT images and evaluated the CT findings of centrilobular GGOs, mosaic pattern, lymph node enlargement, septal lines, pleural effusion, pericardial effusion and pulmonary artery dilatation. GGO was defined as increased opacity of the lung parenchyma that was not sufficient to obscure pulmonary vessels, in contradistinction to true consolidation. Two cardiologists measured the longest diameter of 20 centrilobular GGOs in each right and left upper, middle and lower lobe per patient in patients with PVOD and PCH.

2.6. Statistical analysis

Statistical analysis was performed with SPSS software version 11.0 (SPSS, Chicago, IL, USA). Results are presented as means±standard deviation. Comparisons between patients with PVOD and patients with PCH were assessed by the Mann–Whitney *U* test. Values of $P<.05$ were considered to be statistically significant.

3. Results

3.1. Patient characteristics at chest CT examination

Patient characteristics at HRCT of the chest are shown in Table 1. Patients with IPAH included two males and two females with a mean age of 18.3±6.2 years at HRCT of the chest (No. 1–4). Three patients underwent LDLLT or CLT and one patient was an autopsy case (No. 2). Three patients were treated with a prostaglandin I_2 (PGI_2) analog or intravenous PGI_2 and the other patient was not treated with a PAH-specific drug (endothelin receptor antagonist or phosphodiesterase 5 inhibitor) at HRCT of the chest. Mean pulmonary artery pressure (PAP) was 74.5±25.5 mmHg and mean event-free survival period was 5.1±4.0 years.

Patients with PVOD included two males and one female with a mean age of 32.7±6.2 years at HRCT of the chest (No. 5–7). One patient underwent LDLLT and the other patients were autopsy cases. All patients were treated with a PGI_2 analog or intravenous PGI_2 at HRCT of the chest. Mean PAP was 51.0±10.4 mmHg and mean event-free survival period was 1.2±0.7 years.

Patients with PCH included one male and two females with a mean age of 17.7±5.7 years at HRCT of the chest (No. 8–10). One patient was diagnosed with PCH by open lung biopsy before autopsy (No. 9). The other patients were suspected to have PVOD or PCH clinically. One patient underwent LDLLT and the other patients were autopsy cases. One patient was treated with intravenous PGI_2 and the other patients were not treated with a PAH-specific drug at HRCT of the chest. Mean PAP was 53.5±2.1 mmHg and mean event-free survival period was 1.2±1.3 years.

3.2. Pulmonary function test

Patients with PVOD had a low %DLco (25.9±3.7%) compared with that in patients with IPAH (69.3±10.7%) ($P<.01$). However, there was no significant difference in %DLco between patients with PVOD and patients with PCH.

3.3. Pathological and electron microscopic findings

In a non-pulmonary hypertension control subject, normal small pulmonary arteries and capillary network were observed around the



Fig. 1. Representative pathological findings of lung specimens. Upper panels are hematoxylin and eosin stain images (HE) and lower panels are elastica-van Gieson (EVG) stain images. (A and B) A non-pulmonary hypertension control subject. Normal pulmonary arteries are shown. (C and D) IPAH in a 10-year-old female (Patient No. 1). Intimal and medial hypertrophy was observed in small pulmonary arteries. Small peripheral pulmonary arteries were severely stenosed and occluded and capillaries were deficient. (E and F) PVOD in a 41-year-old man (Patient No. 5). Intimal fibrosis that narrowed the pulmonary veins and completely obliterated venous vessel walls is shown. (G and H) PCH in a 17-year-old female (Patient No.9). Proliferation of capillaries is shown. Bar=500 μm (HE stain and EVG stain).



Fig. 2. Representative pulmonary vascular casts. Upper panels are digital images and lower panels are electron microscopic images. (A and B) A non-pulmonary hypertension subject. Normal capillary network casts are shown. (C and D) Patient with IPAH (Patient No. 5). Small peripheral pulmonary arteries were severely stenosed and occluded and capillaries were deficient. (E and F) Patient with PVOD (Patient No. 7). Some of the capillaries were deficient and others remained to form assemblies. In an electron microscopic image of pulmonary vascular casts, pulmonary capillaries were swollen compared with a normal pulmonary capillary. (G and H) Patient with PCH (Patient No.8). Some of the capillaries were deficient and others remained to form assemblies. In an electron microscopic image of pulmonary vascular casts, the capillary vessels resembled a tumorous cluster. Bar=2 cm (upper panels). Bar=500 μm (B and F). Bar=1 mm (D and H).

alveolus of the lung as previously described [13] (Figs. 1A, B and 2B). In patients with IPAH, intimal and medial hypertrophy was observed (Fig. 1C and D). In an electron microscopic image of pulmonary vascular casts, pulmonary arteries were severely stenosed and occluded and capillaries were deficient (Fig. 2D). In patients with PVOD, intimal fibrosis that narrowed the pulmonary veins and completely obliterated venous vessel walls was shown (Fig. 1E and F). In an electron microscopic image of pulmonary vascular casts, capillaries were swollen compared with a normal capillary (Fig. 2F). In patients with PCH, proliferation of capillaries was shown (Fig. 1G and H). In an electron microscopic image of pulmonary vascular casts, the capillary vessels resembled a tumorous cluster (Fig. 2H).

3.4. Size of centrilobular GGOs in chest HRCT

CT findings are summarized in Table 2. Septal lines and pericardial effusion were shown in all three groups at random. Lymph node enlargements were observed in patients with PCH. All patients had enlarged pulmonary artery diameter. Centrilobular GGOs were shown in all patients with PVOD and PCH (Table 2 and Fig. 3D and F). The size of centrilobular GGOs was larger in patients with PCH than in patients with PVOD (5.60±1.43 mm versus 2.51±0.79 mm, n=60 GGOs in each patient, P<.01) (Fig. 4A). At follow-up, a diffuse micronodular shadow and alveolar hemorrhage were observed in patients with IPAH but centrilobular GGOs were not observed. In patients with PVOD, the size of GGOs at follow-up tended to be larger than that at diagnosis, whereas the size of GGOs at follow-up tended not to be different than that at diagnosis in patients with PCH (Table 3).

3.5. Size of capillary assemblies in pulmonary vascular casts

The longest diameter of capillary assemblies in pulmonary vascular casts was also significantly larger in patients with PCH than in patients with PVOD (5.44±1.71 mm versus 3.07±1.07 mm, n=14 to 16 assemblies in each patient, P<.01) (Figs. 2E, G and 4B).

4. Discussion

PVOD and PCH have been diagnosed pathologically, making it difficult to examine the hemodynamics, reactivity to PAH-specific treatment and survival prospectively. Therefore, clinical diagnosis is important for clinicians to understand these diseases. Results of a pulmonary function test and HRCT findings can suggest a diagnosis of PVOD or PCH. Septal lines, lymph node enlargements, pulmonary artery dilatation, pericardial effusion and pleural effusion are observed in HRCT images of patients with PVOD and PCH [6]. Pulmonary artery dilatation, pericardial effusion and pleural effusion are observed in all patients with IPAH, PVOD and PCH, and these findings are therefore not useful for the differentiation of IPAH, PVOD and PCH. In the present study, pulmonary arteries were dilated in all patients. Septal lines and lymph node enlargement are the most common HRCT findings in patients with PVOD but not in patients with PCH [6,16,22]. However,

Table 2
CT findings

No.	GGOs	Mosaic pattern	Septal lines	LN enlargement	Pleural effusion	Pericardial effusion	ratio PA>1	Therapy at chest CT
1	-	+	+	-	-	-	+	None
2	-	+	-	-	-	+	+	PGI_2 5 ng kg^{-1} min^{-1}
3	-	-	-	-	-	-	+	PGI_2 analog
4	-	-	-	-	-	+	+	PGI_2 8 ng kg^{-1} min^{-1}
5	+	-	+	-	-	-	+	PGI_2 analog
6	+	-	-	-	-	+	+	PGI_2 19 ng kg^{-1} min^{-1}
7	+	-	-	-	-	-	+	PGI_2 9 ng kg^{-1} min^{-1}
8	+	-	-	+	-	-	+	none
9	+	-	+	-	-	+	+	none
10	+	-	+	+	-	+	+	PGI_2 2.5 ng kg^{-1} min^{-1}

GGOs, ground-glass opacities; LN, lymph node; ratio PA, ratio of diameter of the main pulmonary artery to that of the thoracic aorta.



Fig. 3. Representative chest radiographic and HRCT findings. (A and B) IPAH in a 10-year-old female (Patient No. 1). A chest radiograph shows a prominent main pulmonary artery. HRCT shows a small reticulonodular shadow. (C and D) PVOD in a 41-year-old man (Patient No. 5). A chest radiograph demonstrates a prominent central pulmonary artery. HRCT demonstrates small GGOs and septal lines. (E and F) PCH in a 17-year-old female (Patient No.9). A chest radiograph shows a prominent central pulmonary artery. HRCT shows multiple large GGOs and septal lines.

these were observed in HRCT of the chest in both patients with PVOD and PCH in the present study. It has been reported that septal lines and lymph node enlargement were found in HRCT images of patients with PCH [23]. Thus, conventional HRCT findings are insufficient for distinguishing between PVOD and PCH, and clinical differential diagnosis of these diseases has not been established. We previously reported differences in the three-dimensional structures of pulmonary capillary vessels in patients with PAH, PVOD and PCH based on results of scanning electron microscopy of blood vascular casts [13]. PAH was characterized by a deficient capillary network, PVOD was characterized by swollen capillary vessels and PCH was characterized by tumor-like outgrowth of capillaries. These differences in capillaries might reflect differences in the sizes of GGOs in chest HRCT. Thus, we compared the sizes of GGOs in chest HRCT and the sizes of capillary assemblies in pulmonary vascular casts between patients diagnosed pathologically with PVOD and patients diagnosed pathologically with PCH in order to clarify their differences. The present study showed that the sizes of centrilobular GGOs and capillary assemblies were larger in patients with PCH than in patients with PVOD. Measurement of the sizes of centrilobular GGOs is very simple and might be informative for clinical diagnosis of PVOD or PCH.

Centrilobular GGOs are commonly observed in subacute hypersensitivity pneumonitis, bacterial pneumonitis, viral pneumonitis, atypical pneumonitis and interstitial pneumonitis[24]. These diseases are candidates as the first differential diagnosis when GGOs are observed even if PVOD and PCH are suspected clinically. In the present study, none of the patients with PVOD or PCH had fever or laboratory findings of pneumonitis such as elevation of white blood count or C-



Fig. 4. Sizes of GGOs and pulmonary capillary assemblies. (A) Diameter of GGOs. GGOs were significantly larger in patients with PCH than in patients with PVOD. (B) Diameter of pulmonary capillary assemblies. Pulmonary capillary assemblies were significantly larger in patients with PCH than in patients with PVOD.

Table 3
The size of GGOs at diagnosis and follow-up

Patient No.	Diagnosis		At diagnosis	At follow-up	Period between diagnosis and follow-up (days)
5	PVOD	GGOs size (mm)	2.14	3.17	655
		PGI_2 dose (ng kg^{-1} min^{-1})	0	95	
6	PVOD	GGOs size (mm)	2.22	NA	NA
		PGI_2 dose (ng kg^{-1} min^{-1})	19	NA	
7	PVOD	GGOs size (mm)	3.07	3.97	46
		PGI_2 dose (ng kg^{-1} min^{-1})	9	30	
8	PCH	GGOs size (mm)	5.38	5.63	109
		PGI_2 dose (ng kg^{-1} min^{-1})	0	24	
9	PCH	GGOs size (mm)	6.52	6.55	50
		PGI_2 dose (ng kg^{-1} min^{-1})	0	0	
10	PCH	GGOs size (mm)	4.72	4.71	87
		PGI_2 dose (ng kg^{-1} min^{-1})	2.5	24	

Abbreviations as in Table 1 and 2.

reactive protein. Therefore, GGOs in HRCT of the chest in patients with PVOD or PCH were not involved in subacute hypersensitivity pneumonitis, bacterial pneumonitis, viral pneumonitis, atypical pneumonitis or interstitial pneumonitis. Centrilobular GGOs reflect thickening of interstitial tissues, local fluid accumulation in airspaces, local alveoli collapse and increased capillary blood volume [14,15]. In the present study, the size of capillary assemblies was significantly larger in patients with PCH than in patients with PVOD. Since PVOD is characterized by swollen capillary vessels and PCH is characterized by tumor-like outgrowth of capillaries [13], the sizes of capillary assemblies are different. These differences in capillaries might reflect differences in the sizes of centrilobular GGOs in chest HRCT.

The results suggested that measurement of the sizes of centrilobular GGOs in HRCT is a useful method for clinical differential diagnosis of PVOD and PCH compared with the pulmonary function test. However, it is difficult to accurately measure the sizes of centrilobular GGO since the size are affected by many factor. The size of centrilobular GGO can be affected by photographing conditions (slice thickness, kernel used for image reconstruction, caliper size), disease severity (pulmonary edema) and treatment (use of vasodilatation drugs). In the present study, visualization was better in the recent version of HRCT than that in the earlier version of HRCT. If the voxel size is between 0.2 and 0.4 mm, a 20-40% error in measurement is possible. The size of centrilobular GGOs also differs depending on the severity of pulmonary hypertension and PAH-specific drug therapy. Lung congestion sometimes occurs in patients with severe PVOD or PCH. Although intravenous PGI_2 is efficient in patients with IPAH [25], it sometimes causes the occurrence of life-threatening lung congestion in patients with PVOD or PCH [10,26]. In the present study, we excluded one patient with PVOD because that patient had severe pulmonary edema. Widespread pulmonary nodules with diffuse alveolar pulmonary edema were seen in the HRCT images as previously described [27]. We could not measure the size of GGOs in that patient. All patients with PVOD were treated with a PGI_2 analog or intravenous PGI_2, and one patient with PCH was treated with intravenous PGI_2 at HRCT of the chest. In patients with PVOD, the size of centrilobular GGOs at follow-up tended to be larger than that at diagnosis. Titration of PGI_2 dose has been involved in the increase size of centrilobular GGOs in patients with PVOD. On the other hand, the size of centrilobular GGOs at follow-up tended not to be different than that at diagnosis in patients with PCH. The period from HRCT at diagnosis to HRCT at follow-up was short, and this might be the reason for little change in centrilobular GGO size in patients with PCH. Photographing conditions, severity of PH and use of vasodilatation drugs such as PGI_2 might have affected the appearance of centrilobular GGOs.

This study has a limitation. The number of patients was very small. Accumulation of cases of PVOD and PCH is required.

In conclusion, the results of our study with a small sample size showed that the sizes of centrilobular GGOs and capillary assemblies were significantly larger in patients with PCH than in patients with PVOD. Measurement of the size of centrilobular GGOs in HRCT is a simple and useful method for clinical differential diagnosis of PVOD and PCH.

Acknowledgments

The authors thank Kaoru Akazawa, Masayo Ohmori, and Miyuki Fujiwara for their excellent technical assistance.

References

[1] Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S43-54.
[2] Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34(6):1219-63.
[3] Fukumoto Y, Shimokawa H. Recent progress in the management of pulmonary hypertension. Circ J 2011;75(8):1801-10.
[4] Montani D, Achouh L, Dorfmuller P, Le Pavec J, Sztrymf B, Tcherakian C, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008;87(4):220-33.
[5] Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):25S-32S.
[6] Frazier AA, Franks TJ, Mohammed TL, Ozbudak IH, Galvin JR. From the Archives of the AFIP: pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Radiographics 2007;27(3):867-82.
[7] Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334(5):296-302.
[8] Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122(2):156-63.
[9] Montani D, Jais X, Price LC, Achouh L, Degano B, Mercier O, et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J 2009;34(6):1348-56.
[10] Ogawa A, Miyaji K, Yamadori I, Shinno Y, Miura A, Kusano KF, et al. Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Circ J 2012;76(7):1729-36.
[11] Montani D, Price LC, Dorfmuller P, Achouh L, Jais X, Yaici A, et al. Pulmonary veno-occlusive disease. Eur Respir J 2009;33(1):189-200.
[12] Barbosa Jr EJ, Gupta NK, Torigian DA, Gefter WB. Current role of imaging in the diagnosis and management of pulmonary hypertension. AJR Am J Roentgenol 2012;198(6):1320-31.
[13] Miura A, Nakamura K, Kusano KF, Matsubara H, Ogawa A, Akagi S, et al. Three-dimensional structure of pulmonary capillary vessels in patients with pulmonary hypertension. Circulation 2010;121(19):2151-3.
[14] Remy-Jardin M, Remy J, Giraud F, Wattinne L, Gosselin B. Computed tomography assessment of ground-glass opacity: semiology and significance. J Thorac Imaging 1993;8(4):249-64.
[15] Remy-Jardin M, Giraud F, Remy J, Copin MC, Gosselin B, Duhamel A. Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 1993;189(3):693-8.
[16] Resten A, Maitre S, Humbert M, Rabiller A, Sitbon O, Capron F, et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 2004;183(1):65-70.

[17] Murakami T. Application of the scanning electron microscope to the study of the fine distribution of the blood vessels. Arch Histol Jpn 1971;32(5):445-54.
[18] Ogawa A, Nakamura K, Matsubara H, Fujio H, Ikeda T, Kobayashi K, et al. Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Circulation 2005;112(12):1806-12.
[19] Nakamura K, Shimizu J, Kataoka N, Hashimoto K, Ikeda T, Fujio H, et al. Altered nano/micro-order elasticity of pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 2010;140(1):102-7.
[20] Nakamura K, Akagi S, Ogawa A, Kusano KF, Matsubara H, Miura D, et al. Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 2012;159(2):100-6.
[21] Hashimoto K, Nakamura K, Fujio H, Miyaji K, Morita H, Kusano K, et al. Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension. Circ J 2004;68(3):227-31.
[22] Dufour B, Maitre S, Humbert M, Capron F, Simonneau G, Musset D. High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. AJR Am J Roentgenol 1998;171(5):1321-4.
[23] El-Gabaly M, Farver CF, Budev MA, Mohammed TL. Pulmonary capillary hemangiomatosis imaging findings and literature update. J Comput Assist Tomogr 2007;31(4):608-10.
[24] Collins J, Stern EJ. Ground-glass opacity at CT: the ABCs. AJR Am J Roentgenol 1997;169(2):355-67.
[25] Akagi S, Nakamura K, Miyaji K, Ogawa A, Kusano KF, Ito H, et al. Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. Circ J 2010;74:2200-5.
[26] Resten A, Maitre S, Humbert M, Sitbon O, Capron F, Simoneau G, et al. Pulmonary arterial hypertension: thin-section CT predictors of epoprostenol therapy failure. Radiology 2002;222(3):782-8.
[27] Montani D, O'Callaghan DS, Savale L, Jais X, Yaici A, Maitre S, et al. Pulmonary veno-occlusive disease: recent progress and current challenges. Respir Med 2010;104(Suppl. 1):S23-32.

Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension

Results of the Randomized IMPRES Study

Marius M. Hoeper, MD; Robyn J. Barst, MD; Robert C. Bourge, MD; Jeremy Feldman, MD; Adaani E. Frost, MD; Nazzareno Galié, MD; Miguel Angel Gómez-Sánchez, MD; Friedrich Grimminger, MD; Ekkehard Grünig, MD; Paul M. Hassoun, MD; Nicholas W. Morrell, MD; Andrew J. Peacock, MD; Toru Satoh, MD; Gérald Simonneau, MD; Victor F. Tapson, MD; Fernando Torres, MD; David Lawrence, PhD; Deborah A. Quinn, MD; Hossein-Ardeschir Ghofrani, MD

Background—By its inhibitory effect on platelet-derived growth factor signaling, imatinib could be efficacious in treating patients with pulmonary arterial hypertension (PAH).

Methods and Results—Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES), a randomized, double-blind, placebo-controlled 24-week trial, evaluated imatinib in patients with pulmonary vascular resistance ≥800 dyne·s·cm^{-5} symptomatic on ≥2 PAH therapies. The primary outcome was change in 6-minute walk distance. Secondary outcomes included changes in hemodynamics, functional class, serum levels of N-terminal brain natriuretic peptide, and time to clinical worsening. After completion of the core study, patients could enter an open-label long-term extension study. Of 202 patients enrolled, 41% patients received 3 PAH therapies, with the remainder on 2 therapies. After 24 weeks, the mean placebo-corrected treatment effect on 6-minute walk distance was 32 m (95% confidence interval, 12–52; P=0.002), an effect maintained in the extension study in patients remaining on imatinib. Pulmonary vascular resistance decreased by 379 dyne·s·cm^{-5} (95% confidence interval, −502 to − 255; P<0.001, between-group difference). Functional class, time to clinical worsening, and mortality did not differ between treatments. Serious adverse events and discontinuations were more frequent with imatinib than placebo (44% versus 30% and 33% versus 18%, respectively). Subdural hematoma occurred in 8 patients (2 in the core study, 6 in the extension) receiving imatinib and anticoagulation.

Conclusions—Imatinib improved exercise capacity and hemodynamics in patients with advanced PAH, but serious adverse events and study drug discontinuations were common. Further studies are needed to investigate the long-term safety and efficacy of imatinib in patients with PAH.

Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00902174 (core study); NCT01392495 (extension). ***(Circulation.* 2013;127:1128-1138.)**

Key Words: drugs ■ exercise ■ hemodynamics ■ hypertension, pulmonary

Pulmonary arterial hypertension (PAH) is characterized by progressive obliteration of the pulmonary vascular bed, eventually leading to right heart failure and death if not treated effectively.[1,2] Although some forms of PAH are heritable or associated with other conditions such as scleroderma, many cases are idiopathic in origin.[3]

Editorial see p 1098
Clinical Perspective on p 1138

The median survival of patients with idiopathic or heritable PAH was >3 years before the availability of targeted PAH drugs.[4] Current treatment options consist of prostacyclin and

Received July 30, 2012; accepted January 14, 2013.

From Medizinische Hochschule, Hannover, Germany (M.M.H.); Columbia University, New York, NY (R.J.B.); University of Alabama at Birmingham (R.C.B.); Arizona Pulmonary Specialists, Phoenix (J.F.); Baylor College of Medicine, Houston, TX (A.E.F.); Università di Bologna, Bologna, Italy (N.G.); Hospital Universitario Doce de Octubre, Madrid, Spain (M.A.G.-S.); University Hospital Giessen and Marburg GmbH, Giessen, Germany (F.G., H.G.); University Hospital Heidelberg, Heidelberg, Germany (E.G.); Johns Hopkins University, Baltimore, MD (P.M.H.); University of Cambridge School of Clinical Medicine, Addenbrooke's and Papworth Hospitals, Cambridge, United Kingdom (N.W.M.); Golden Jubilee National Hospital, Glasgow, United Kingdom (A.J.P.); Kyorin University School of Medicine, Tokyo, Japan (T.S.); Hôpital de Bicêtre, Le Kremlin-Bicêtre, Paris, France (G.S.); Duke University Medical Center, Durham, NC V.F.T.); University of Texas Southwestern Medical Center, Dallas (F.T.); Novartis Pharmaceuticals, East Hanover, NJ (D.L.); and Novartis Pharmaceuticals, Cambridge, MA (D.A.Q.).

The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.112.000765/-/DC1.

Correspondence to Marius M. Hoeper, MD, Department of Respiratory Medicine, Hannover Medical School, 30623 Hannover, Germany. E-mail hoeper.marius@mh-hannover.de

Circulation **is available at http://circ.ahajournals.org** **DOI: 10.1161/CIRCULATIONAHA.112.000765**

its analogues, endothelin receptor antagonists, and phosphodiesterase type-5 inhibitors, all of which have been shown to improve exercise capacity, hemodynamic variables, and disease progression,[5–10] together with calcium channel blocker therapy in the rare patient responding to vasodilators and lung transplantation in the patients who are refractory to medical therapy. However, normalization of pulmonary vascular resistance (PVR) with long-term improvement is rarely achieved, even with combination treatment, and survival rates remain poor. Humbert and colleagues[11,12] recently reported a 3-year survival of <60% in patients with newly diagnosed PAH despite current therapy, highlighting the need for more treatment options.

Once considered a consequence of abnormal pulmonary vasoconstriction, PAH is now regarded as a disease caused mainly by pulmonary vascular remodeling. Proliferation of endothelial cells and vascular smooth muscle cells with narrowing or occlusion of the vessel lumina is a histopathological hallmark of the disease.[13] Evidence from animal models and human disease suggests that platelet-derived growth factor (PDGF) and c-KIT signaling are important in vascular smooth muscle cell proliferation and hyperplasia.[14–16]

Imatinib is an antiproliferative agent developed to target the BCR-ABL tyrosine kinase in patients with chronic myeloid leukemia. In addition, the inhibitory effects of imatinib on PDGF receptors α and β and c-KIT suggest that it may be efficacious in PAH.[15–17] Imatinib reversed experimentally induced pulmonary hypertension[17] and has pulmonary vasodilatory effects in animal models[18] and proapoptotic effects on pulmonary artery smooth muscle cells from patients with idiopathic PAH.[19] Case reports have suggested hemodynamic and clinical benefits in PAH patients.[20–22] A randomized, double-blind, placebo-controlled phase II study in 59 patients reported that imatinib significantly improved pulmonary hemodynamics.[23] In that study, a post hoc subgroup analysis suggested that patients with greater hemodynamic impairment might respond better to imatinib than patients with less advanced disease. The objective of the present study was to further evaluate the safety, tolerability, and efficacy of imatinib in patients with advanced PAH who were receiving at least 2 PAH therapies.

Methods

Patients

The study was conducted at 71 centers in 14 countries. Male and female subjects (aged ≥18 years) were enrolled if they had symptomatic PAH (World Health Organization functional class II through IV)[24] and met the criteria for one of the following categories of group 1 pulmonary hypertension: idiopathic or heritable PAH; PAH associated with connective tissue disease; PAH after ≥1 year repair of congenital systemic to pulmonary shunt; or PAH associated with anorexigens or other drugs.[25] Patients were required to be receiving at least 2 PAH therapies (endothelin receptor antagonists, phosphodiesterase type-5 inhibitors, or prostacyclin analogues for ≥3 months) with a PVR ≥800 dyne·s·cm^{-5} at screening (see Appendix I in the online-only Data Supplement). Patients with World Health Organization functional class IV PAH were required to be receiving a prostacyclin analogue unless shown to be intolerant. Full details of enrollment criteria are in the protocol (Appendix II in the online-only Data Supplement).

Study Design and Treatments

Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES) was a 24-week, multicenter, double-blind, placebo-controlled, parallel-group study. Eligibility was determined in a 6-week screening period. Baseline 6-minute walk distance (6MWD) was derived from the mean of 2 consecutive tests with results that fell within 15% of each other.

Eligible patients were randomized in a 1:1 ratio to imatinib or placebo at an intended starting dose of 200 mg once daily (see Appendix I in the online-only Data Supplement). The dose was increased to 400 mg once daily after 2 weeks if the starting dose was tolerated; the dose could be reduced to 200 mg once daily if the 400 mg dose was not well tolerated. Patients were withdrawn from the trial after dose reduction if any of the following persisted for ≥2 weeks: liver function test ≥4 times the upper limit of normal; creatinine >1.5 times the upper limit of normal or >30% versus screening value; weight gain >2 kg when due to edema and decline in right heart function; or incapacitating peripheral edema or nausea/vomiting.

All patients gave written, informed consent to participate in the study. The study protocol was approved by ethics committees and/or institutional review boards at each study center.

Study Assessments

The primary efficacy end point was change in 6MWD from baseline to week 24. Six-minute walk tests were performed according to American Thoracic Society guidelines.[26] Secondary efficacy end points included changes in pulmonary hemodynamics and time to clinical worsening.

Hemodynamic variables were determined with the use of right heart catheter assessments at baseline and end of study. Time to clinical worsening was determined on the basis of time from baseline to the first occurrence of any of the following: death; overnight hospitalization for worsening of PAH (blind adjudication); worsening of World Health Organization functional class by at least 1 level; or ≥15% decrease from baseline in 6MWD (confirmed in 2 six-minute walk tests at 2 consecutive visits). Blood samples were collected for laboratory assessments, including measurement of N-terminal pro-B-type natriuretic peptide, at baseline and subsequent study visits. Safety assessments included echocardiographic assessment at baseline, week 12, and week 24 and monitoring and recording of all adverse events (AEs). All deaths and unplanned overnight hospitalizations were adjudicated by an independent committee to determine whether they were due to worsening PAH. Laboratory tests and ECGs were obtained at each visit. Patients in the core study were followed for 24 weeks after they received the first dose of study drug.

Long-term Extension Study

After completion of the 24-week core study, patients were eligible to enter a long-term open-label extension study (ongoing). Patients who were treated with 400 mg once daily of imatinib during the core study remained on 400 mg once daily, those who were treated with 200 mg once daily during the core study remained on 200 mg once daily, and those who were treated with placebo during the core study were started on 200 mg once daily and then uptitrated to 400 mg once daily after 2 weeks. Titration of dose between 200 and 400 mg was allowed on the basis of drug tolerability.

Statistical Analyses

Statistical power was estimated on the basis of 6MWD, drug tolerability (dropouts), and outcomes from prior studies. With assumption of a 30% dropout rate at 6 months, a sample size of 70 patients per group was calculated to detect a 50-m difference between imatinib and placebo with a SD of 75 m, an α of 5% (2-sided), and 90% power. Additional patients were included to enable analysis of time to clinical worsening.

Efficacy was assessed in all randomized patients who received at least 1 dose of study drug. Patients were analyzed according to randomized treatment. The assessment of 6MWD used a mixed-effects

model for repeated measures, including treatment, week, and country as factors, and baseline 6MWD as a covariate as well as treatment-by-week and 6MWD baseline-by-week interactions. A random effect of center within country was also included. For the primary analysis, the null hypothesis (no change in 6MWD between imatinib and placebo at week 24) was rejected if the 2-sided P value was >5% and the confidence interval (CI) was entirely >0. Pulmonary hemodynamics were analyzed with a mixed-effects model including treatment and country as factors and baseline hemodynamic values as covariates. The random effect of center within country was also included in the model. Time to clinical worsening was analyzed with a Cox regression model, with terms for treatment and country and with baseline 6MWD as a covariate. Patients who discontinued the study were considered censored. Full details of the statistical approach, including sensitivity analyses and imputation rules for missing variables, are provided in the online-only Data Supplement.

Dr Hoeper, the Principal Investigator, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors were involved in the writing of the manuscript and saw and approved the final version.

Results

Patient Disposition, Characteristics, and Drug Exposure

A total of 103 patients were randomized to imatinib and 99 to placebo (Figure 1) between September 17, 2009, and May 12, 2011. One patient in the placebo group was randomized but did not receive study treatment. Baseline demographic and clinical characteristics were well balanced (Table 1). Long-term dose escalation (receipt of 400 mg once daily for ≥77 days) was successful in 48 imatinib-treated patients (47%) and 86 placebo recipients (88%).

Efficacy

Imatinib significantly improved 6MWD at week 24 compared with placebo, with a mean between-group difference of 32 m (95% CI, 12–52; P=0.002). Sensitivity analyses including multiple imputations for missing values retained statistical significance, although the treatment effects were slightly attenuated (Table 2). A post hoc sensitivity analysis using nonparametric statistical methods and imputation for missing values similar to other published trials[9] was performed (treatment effect, 29 m; 95% CI, 7–50; P=0.010) (Table 2 and Appendix I in the online-only Data Supplement).

Improvements in 6MWD from baseline with adjustment for covariates including baseline 6MWD were statistically significant from week 12 onward (Figure 2A). A responder analysis by thresholds of improvement in 6MWD is provided in Appendix III and Table I in the online-only Data Supplement. The change in 6MWD (with the use of last observation carried forward to week 24) remained significant in the subgroup of patients receiving triple combination therapy at baseline (between-group difference, 34 m; 95% CI, 5–62; P=0.021; Figure 2B).

In the patients who remained on imatinib in the extension (n=66), improvements in 6MWD at week 24 of the core study were maintained at week 24 of the extension (total of 48 weeks on imatinib; n=54). In these patients, 6MWD increased by 44.7±45.5 m (mean±SD) compared with core study baseline. In comparison, in patients treated with placebo in the core study and imatinib in the extension (total of 24 weeks on imatinib; n=53), the 6MWD increased by 19.3±71.6 m (mean±SD) compared with the core study baseline.

Patients receiving imatinib had greater improvements in hemodynamics. PVR decreased by 367 dyne·s·cm^{-5} in imatinib-treated patients (n=74) and increased by 12 dyne·s·cm^{-5} in placebo recipients (n=80), with a between-group difference of 379 dyne·s·cm^{-5} (95% CI, −502 to −255; P<0.001), equating to a change of −31.8% (95% CI, −42.2 to −21.4; P<0.001). In addition, mean pulmonary artery pressure



Figure 1. Patient disposition. *Two additional deaths occurred, 1 in each group, within 30 days of study drug discontinuation. †Long-term dose escalation was defined as ≥77 days (ie, ≥50% of the 22-week period during which patients could receive imatinib 400 mg).

Table 1. Baseline Demographic and Clinical Characteristics

	Imatinib (n=103)	Placebo (n=98)
Age, median (range), y	50 (18–77)	47 (18–77)
Age distribution, n (%)		
18–39 y	28 (27)	35 (36)
40–64 y	57 (55)	54 (55)
≥65 y	18 (18)	9 (9)
Male/female sex, n (%)	20 (19)/83 (81)	19 (19)/79 (81)
Race, n (%)		
White	77 (75)	72 (74)
Black	4 (4)	5 (5)
Asian	19 (18)	20 (20)
Other	3 (3)	1 (1)
PAH duration, median (range), y	3.7 (0–41)	5.1 (0–17)
Type of PAH, n (%)		
Idiopathic or heritable	77 (75)	74 (76)
Associated with other conditions	26 (25)	23 (24)
Other	0	1 (1)
WHO functional class, n (%)		
Class I	1 (1)	0
Class II	23 (22)	28 (29)
Class III	71 (69)	65 (66)
Class IV	8 (8)	5 (5)
PAH-specific background therapy, n (%)*		
ERA and PDE5	32 (31)	27 (28)
ERA and PG	15 (15)	10 (10)
PG and PDE5	14 (14)	20 (20)
ERA and PDE5 and PG	42 (41)	41 (42)
6MWD, median (range), m	355 (154–450)	366 (153–446)
Hemodynamics, mean (SD)		
Right atrial pressure, mm Hg	10 (6)	10 (7)
Mean pulmonary arterial pressure, mm Hg	59 (11)	60 (13)
Pulmonary capillary wedge pressure, mm Hg	9 (3)	9 (3)
Cardiac output, L/min	3.5 (0.9)	3.5 (0.7)
Cardiac index, L/min per m^2	2.1 (0.5)	2.1 (0.5)
Pulmonary vascular resistance, dyne·s·cm^{-5}	1202 (414)	1181 (360)

6MWD indicates 6-minute walk distance; ERA, endothelin receptor antagonists; PAH, pulmonary arterial hypertension; PDE5, phosphodiesterase type-5 inhibitors; PG, prostacyclin analogues; and WHO, World Health Organization.

*In total, 69% of imatinib patients and 72% of placebo patients were treated with prostacyclin analogues. By formulation, 31% and 28% of patients received intravenous, 17% and 16% of patients received inhaled, 15% and 17% of patients received subcutaneous, and 7% and 11% of patients received oral prostacyclin analogues in the imatinib and placebo groups, respectively.

(imatinib/placebo, n=75/82), cardiac output (imatinib/placebo, n=75/81), and right atrial pressure (imatinib/placebo, n=73/81) improved compared with placebo (all $P \leq 0.03$; Figure 3; additional data are available in Appendix III and Table II in the online-only Data Supplement). The hemodynamic effects observed in patients with PAH associated with connective tissue disease or repaired congenital heart disease were similar to the hemodynamic changes seen in patients with idiopathic or heritable PAH, but the subgroups were too small to allow robust statistical analyses (Appendix III and Table III in the online-only Data Supplement). Similarly, improvements versus placebo were demonstrated with imatinib for 6MWD and PVR in patients in functional classes II and III (Appendix III and Table IV in the online-only Data Supplement).

At week 24, N-terminal pro-B-type natriuretic peptide levels (mean±SE) were lower in the imatinib group (n=68; 142±39 pmol/L) than in the placebo group (n=78; 188±40 pmol/L), with a mean difference of −45 pmol/L (95% CI, −88 to −2 pmol/L; P=0.040).

There was no significant difference in functional class at 24 weeks (imatinib, n=70; placebo, n=83). There was also no

Table 2. Sensitivity Analyses of the Primary End Point (6-Minute Walk Distance at Week 24) Including Imputation for Missing Data

	LS Mean Treatment Difference, Imatinib–Placebo at Week 24, m (95% CI)	P
Primary analysis (repeated-measures ANCOVA)	32 (12–52)	0.002
Univariate ANCOVA using LOCF	27 (7–47)	0.008
Univariate ANCOVA using BOCF	20 (5–35)	0.010
Modified multiple imputation using penalties* (repeated-measures ANCOVA)		
0% penalty	34 (14–54)	0.001
2% penalty	33 (13–53)	0.001
8% penalty	28 (8–48)	0.005
10% penalty	27 (7–47)	0.008
Multiple imputations using information from placebo patients (repeated-measures ANCOVA)†	27 (6–48)	0.013
Multiple imputations for specific reasons for discontinuation using information from placebo patients (repeated-measures ANCOVA)‡	28 (7–50)	0.009
Imputation based on published trials, CMH test		0.013
Imputation based on published trials, univariate ANCOVA	29 (7–50)	0.010

For full details of statistical methodology used to perform sensitivity analyses with adjustment for missing data, please refer to Appendix I in the online-only Data Supplement. BOCF indicates baseline observation carried forward; CI, confidence interval; CMH, Cochrane Mantel-Haenszel test; LOCF, last observation carried forward; and LS, least squares.

*Penalties were applied to patients in the imatinib arm, assuming a lower postwithdrawal 6-minute walk distance for patients who discontinued because of adverse events, unsatisfactory therapeutic effect, or death than for patients who remained in the study (allowing for the possibility of data being "missing not at random"). The scenarios investigated were 98%, 95%, 92%, and 90% lower 6-minute walk distance compared with imputations that assume that the data are missing at random.

†For patients in the active arm who discontinued for any reason, missing values were imputed on the basis of information of other patients who discontinued and placebo patients only.

‡For patients in the active arm who discontinued because of adverse events, unsatisfactory therapeutic effect, or death, missing values were imputed on the basis of information of other patients who discontinued for these reasons and placebo patients only.

significant difference in time to first clinical worsening event (hazard ratio, 1.16; 95% CI, 0.71–1.90; P=0.563) (Figure 4). During the study, 37 imatinib-treated patients (36%) had a clinical worsening event compared with 32 placebo recipients (33%) (Table 3). A detailed list of the timing of these events is shown in Appendix III and Table V in the online-only Data Supplement. Among the 37 clinical worsening events observed in the imatinib group, 24 occurred during the first 8 weeks. Of the 37 imatinib patients who experienced clinical worsening events, 15 continued on study drug and had a mean improvement in 6MWD of 15 m at the end of the study (Appendix III and Figure I in the online-only Data Supplement).

Safety

All patients including withdrawals were followed for survival data until 24 weeks after they received the first dose of study drug. Five patients in each group died during the core study (2 deaths in each group while on study drug and 3 deaths in each group after discontinuation of study drug [Appendix III and Table VI in the online-only Data Supplement]). One death in the imatinib group (renal failure) and 1 in the placebo group (clostridial infection) were considered by the respective investigators to be related to the study drug.

During the study, 28 patients (27%) discontinued because of AEs in the imatinib group compared with 9 (9%) in the placebo group, with the majority in both groups discontinuing in the first 8 weeks. The most frequent AEs were nausea, peripheral edema, diarrhea, vomiting, and periorbital edema, all known side effects of imatinib (Table 3; for additional data, see Appendix III and Tables VII through IX in the online-only Data Supplement). Anemia, leucopenia, and thrombocytopenia were observed in 14% (5% severe), 2% (0% severe), and 5% (1% severe) of imatinib patients, respectively. Serious AEs were also more frequent with imatinib than with placebo (Table 3).

Echocardiographic assessments did not show any evidence of cardiac dysfunction associated with imatinib therapy (Appendix III and Table X in the online-only Data Supplement). In addition, there was no indication of renal toxicity or hepatotoxicity due to imatinib therapy.

Long-Term Extension Study

Of the 150 patients completing the 24-week core study, 144 patients entered the extension study; 6 declined. As of March 16, 2012, of the 144 patients enrolled in the extension, 60 had withdrawn (32 of 60 because of AEs). As of October 31, 2012, a total of 18 patients had died in the extension, with 8 deaths in the core imatinib group (n=66) and 10 in the core placebo



Figure 2. A, Change in 6-minute walk distance (6MWD) from baseline by treatment. Values are least squares means and SEs. *P* values are for between-group comparisons from ANCOVA of change from baseline in 6MWD (m) at each time. Sixty-nine patients receiving imatinib and 81 patients receiving placebo completed the study. Three patients receiving imatinib and 1 patient receiving placebo did not have a 6MWD test on completion. **B**, Subgroup analysis of changes from baseline in 6MWD (m) to end of study according to background therapy. Data are least squares mean change (m) with 95% confidence intervals. ERA indicates endothelin receptor antagonists; PDE5, phosphodiesterase type-5 inhibitors; and PG, prostacyclin analogues.

group (n=78). Fifteen of these deaths occurred while the subject was on imatinib or within 30 days of discontinuation (5 core imatinib and 10 core placebo patients), whereas 3 occurred >30 days after discontinuation (all from the core imatinib group). Sixteen deaths have been adjudicated, and 7 have been attributed to progression of PAH (3 core imatinib and 4 core placebo patients). None of these deaths were considered to be related to imatinib toxicity by the Adjudication Committee (Appendix III and Tables VI and XI in the online-only Data Supplement).

The most frequent AEs (>10%) during the extension were similar to those in the core study (Appendix III and Table XII in the online-only Data Supplement). Fifty-three percent of patients experienced serious AEs. Serious AEs that occurred in ≥3% of patients were cardiac failure (4.2%), subdural hematoma (4.2%), dyspnea (4.2%), worsening PAH (4.9%), syncope (4.9%), and device-related infection (3.5%).

Subdural hematomas occurred in 8 patients (2 of 103 imatinib patients in the core study [1.9%]; 6 of 144 patients in the extension [4.2%]) on imatinib and concomitant anticoagulation. Six patients recovered, 1 died of subdural hematoma, and 1 died of unrelated causes (Appendix III and Table XIII in the online-only Data Supplement).

In the IMPRES core study, there were no patients who received a lung transplantation on imatinib and 4 patients who received lung transplantation on placebo. Six extension study patients have undergone transplantation. Patients who underwent lung transplantation were withdrawn from the study, and imatinib treatment was stopped. No evidence of surgical complications attributable to imatinib has been identified. Although these discontinued patients are no longer in the study, reports of 2 extension study patients with serious AEs after the lung transplantation have been received. One patient had a cerebrovascular accident 2 days after transplantation, and 1 patient was reported to have died of complications related to the transplantation ≈4.5 months after the procedure.

Discussion

This multicenter, randomized, double-blind, placebo-controlled 24-week study demonstrates that imatinib improves exercise capacity and hemodynamics in patients with advanced PAH despite combination therapy with ≥2 PAH drugs. For all currently approved drugs, the 6-minute walk test was the primary end point or part of a primary composite end point. Studies of 3- to 4-month duration in patients who were treatment-naive to PAH therapies showed placebo-corrected changes in 6MWD of 31 to 50 m.[7–10] More recent trials in patients on a single background PAH therapy showed improvements in 6MWD of 20 to 26 m.[27,28] Unlike most previous phase III trials, the present study enrolled patients who were receiving a combination of at least 2 PAH therapies, with 41% on triple therapy including 29% on continuous parenteral prostanoid infusion. Against this background therapy, the 32-m improvement in 6MWD with imatinib after 6 months of treatment was not only statistically significant but also clinically meaningful,[29] especially in light of the currently available treatment options having been exhausted in many of these patients.

The present study also showed that imatinib resulted in significantly improved hemodynamic parameters. The mean placebo-adjusted improvements in cardiac output and PVR were 0.88 L/min and −379 dyne·s·cm^{-5}, respectively. The magnitude of hemodynamic improvement is remarkable given that all patients had severe PAH, with an average baseline PVR of ≈1200 dyne·s·cm^{-5} despite already being on multiple PAH treatments. Consistent with the changes in 6MWD, these hemodynamic differences were almost entirely due to improvements in patients randomized to imatinib rather than to deterioration in the placebo group. The improvements in cardiac output were accompanied by significant decreases in serum N-terminal pro-B-type natriuretic peptide.

Time to clinical worsening, a composite end point including all-cause mortality, hospitalization for worsening PAH, worsening of World Health Organization functional class, or a decrease in 6MWD of >15% from baseline, did not differ between the 2 treatment groups. Further analysis of these events suggests that the majority of the events in the imatinib group occurred during the first 8 weeks of the study in patients who did not tolerate the study medication and who had their dose reduced or who discontinued the study